{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:42:08Z","timestamp":1760244128004,"version":"build-2065373602"},"reference-count":16,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Heart failure with reduced ejection fraction (LV-EF &lt; 35%) is diagnosed in app. 11,000,000 patients worldwide. For the treatment of these patients, guideline directed medical therapy has proven to reduce mortality and rehospitalization regardless of the disease\u2019s etiology. It is implemented to treat clinical symptoms by improving the left ventricular ejection fraction. Patients with a transient risk of ventricular tachycardia and sudden cardiac death can be protected by a defibrillator vest. The defibrillator vest is capable to detect and terminate ventricular arrhythmias during Guideline Directed Medical Therapy (GDMT). It is based on the recommendations of the European society of cardiology for 3 months. Afterwards, the WCD wear time could be prolonged, or, in case of persistent low ejection fraction (LV-EF \u2264 35%), an implantable cardioverter defibrillator (ICD) should be implanted, as shown in the WEARIT-II-registry. Our goal was to evaluate the effects of GDMT on LV-recovery and reduction of ICD implantations under protection with a defibrillator vest\u2014depending on the uptitration of GDMT. Methods: 339 consecutive patients between August 2017 and September 2020 with newly diagnosed cardiomyopathy and an EF \u2264 35% were analyzed retrospectively by chart review. All patients were protected by a wearable cardioverter defibrillator (WCD). GDMT as recommended by the ESC started at discharge from hospital. The left ventricular ejection fraction (LV-EF) was determined by transthoracic echocardiography at week 4, 8 and at week 12 (in case of prolonged WCD wear time). Uptitration was performed after 4 and 8 weeks during patient visits. We focused on baseline medication as per GDMT and the dosage increase at week 4, 8 and 12. The aim was the uptitration to the maximum dosage tolerated by the patient. We also compared the LV-EF improvement in the group with and without uptitration of medication dosage. Results: The patient age was, on average, 63.2 years (SD \u00b1 11.9 years). A total of 129 pts (38%) had ICM, 196 (58%) had NICM (incl 66 pts (19%) with DCM and 51 pts (15%) with Myocarditis, 79 pts (24%) with unknown origin) and 14 pts (4%) had other entities (e.g., Tachycardiomyopathy). In total, 21 pts (6%) had an LV-EF of less than 16%, 130 pts (38%) between 16\u201325% and 183 pts (54%) between 26\u201335%. GDMT started at discharge from the hospital included treatment with beta blocker for 327 pts (96.5%), ACE-inhibitors\/Angiotensin\/ARNI for 283 pts (83.5%) and Mineralcorticoid receptor antagonists (MRA) for 334 pts (88.4%). Uptitration was performed in all groups at a rate of 82.3%, 91.1% and 81.0% after 4 weeks and 64.7%, 50.3% and 66.3% after 8 weeks, respectively. After 4 weeks, 25 pts (7.4%) and, after 8 weeks, 171 pts (50.4%) had an EF increase of 5% or more (mean 14.2%). After 4 weeks, 81 patients had an LV-EF more than 35%. A total of 169 pts had a wear time of 12 weeks and an improvement of LVEF of more than 35%. Interestingly, in our study we did not find a significant difference in LV-EF improvement between the group with no uptitration and the group with uptitration. Conclusions: Guideline-directed medical therapy under protection with a WCD from ventricular arrhythmia can reduce the need for implantation of an ICD and can lead to an improvement of ejection fraction. Interestingly, the LV-EF improvement depends on the GDMT at discharge. Current guidelines recommend an initiation of all therapy columns of GDMT (sacubitril\/valsartan, ACE-inhibitor\/AT1-blocker, mineralcorticoidreceptorblocker, beta blocker) at once and further uptitration to the maximal dosage (ESC Guidelines 2021). A further uptitration of all drugs of GDMT should lead to improvement of LV-EF and consequently to a reduction in ICD implantations.<\/jats:p>","DOI":"10.3390\/jcm11206122","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:31:01Z","timestamp":1666053061000},"page":"6122","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guideline Directed Medical Therapy at Discharge and Further Uptitration Leading to Reduction in Indication for Prophylactic ICD Implantation during Protected Waiting Period"],"prefix":"10.3390","volume":"11","author":[{"given":"Elias","family":"Waezsada","sequence":"first","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Hutter","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Kahle","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Yogarajah","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Sperzel","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Kuniss","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Neumann","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Esser","sequence":"additional","affiliation":[{"name":"Zoll CMS GmbH, 50996 Koeln, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hamm","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hain","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, 61231 Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15829\/1560-4071-2017-1-7-81","article-title":"2016 Esc guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC): Developed with the special contribution","volume":"1","author":"Ponikowski","year":"2017","journal-title":"Russ. J. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1161\/CIRCULATIONAHA.105.561423","article-title":"Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients","volume":"112","author":"Solomon","year":"2005","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMoa0901889","article-title":"Defibrillator Implantation Early after Myocardial Infarction","volume":"361","author":"Steinbeck","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa041489","article-title":"Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction","volume":"351","author":"Hohnloser","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/eurheartj\/ehp425","article-title":"Predictors of sudden cardiac death change with time after myocardial infarction: Results from the VALIANT trial","volume":"31","author":"Piccini","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_6","first-page":"1601","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europea","volume":"11","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12181-019-0331-4","article-title":"Der tragbare Kardioverter\/Defibrillator (WCD)\u2014Indikationen und EinsatzWearable cardioverter defibrillator (WCD)\u2014Indications and use","volume":"13","author":"Deneke","year":"2019","journal-title":"Der Kardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure","volume":"70","author":"Yancy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MLR.0000000000000492","article-title":"Post-discharge follow-up characteristics associated with 30-day readmission after heart failure hospitalization","volume":"54","author":"Lee","year":"2016","journal-title":"Med. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2015.12.046","article-title":"Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation","volume":"67","author":"Roth","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e004512","DOI":"10.1161\/JAHA.116.004512","article-title":"Avoiding untimely implantable cardioverter\/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter\/defibrillator-the PROLONG study","volume":"6","author":"Duncker","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJMoa1800781","article-title":"Wearable Cardioverter\u2013Defibrillator after Myocardial Infarction","volume":"379","author":"Olgin","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel","volume":"108","author":"Martens","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.118.035452","article-title":"Timely Management of New-Onset Heart Failure","volume":"140","author":"Gracia","year":"2019","journal-title":"Circulation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/6122\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:56:08Z","timestamp":1760144168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/6122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":16,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11206122"],"URL":"https:\/\/doi.org\/10.3390\/jcm11206122","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,10,18]]}}}